|
|
home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA) |
 |
 |
WHITE PAPERS |
|
PRA Health Sciences (PRA)
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
|
Governments, healthcare payers, and social and health reforms, combined
with the increased incidence of conditions such as cancer and diabetes
are paving the way for increased uptake of biologic medicines in
emerging markets. However, expensive biologic medicines can be
prohibitive to many patients, creating a high level of unmet clinical
need. At its best, the global expansion of biosimilars can mean a robust
and steady supply of existing and new drugs reaching far-flung patient
populations, but localized biosimilar drug developments, especially in
China and India, combined with a lack of robust pharmacovigilance
systems, threaten to derail the industry by putting patient health at
risk.
|
|
|
|
|
 |
 |
News and Press Releases |
 |
Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases
Funding accelerates development of late-stage cancer therapies, pipeline expansion and business growth
Syndicate includes all Series A investors, preeminent life science and generalist funds, and market-leading health systems and payers
More info >> |
|
 |
White Papers |
 |
Investigator Portals: Facilitating and Streamlining Communication & Collaboration with Study Sites
ArisGlobal
ArisGlobal LLC
Investigator site personnel are often frustrated with the lack of transparency and communication with their sponsors, leading to significant dissatisfaction and withdrawal from current and future studies. The adoption of investigator portals gives sponsors a platform that fosters collaboration and improves site management. Learn about five key areas of sponsor-investigator site interactions deserving of electronic communication and collaboration. Technology and design aspects are also covered.
More info >> |
|
 |
Industry Events |
 |
DIA Europe 2021
15-19 March 2021, VIRTUAL CONFERENCE
DIA Europe is the must-attend event for all life science professionals
working in drug development, from discovery to marketed use. It
encourages open collaboration by bringing together representatives from
the entire spectrum of the life science landscape and facilitating
crucial discussions across several topic tracks: Clinical Development,
Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy,
and many more.
More info >> |
|
|
|